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Abstract Placental type 3 iodothyronine deiodinase (D3)
potentially protects the fetus from the elevated maternal
thyroid hormones. Na+/I− symporter (NIS) is a plasma mem-
brane glycoprotein, which mediates active iodide uptake.
Our objectives were to establish the distribution of NIS and
D3 gene expressions in the placenta and the amniotic mem-
brane and to investigate the relationship between placental
D3 and NIS gene expressions and maternal iodine, selenium,
and thyroid hormone status. Thyroid hormones, urinary io-
dine concentration (UIC), and selenium levels were mea-
sured in 49 healthy term pregnant women. NIS and D3 gene
expressions were studied with the total mRNA RT-PCR
method in tissues from maternal placenta (n=49), fetal
placenta (n=9), and amniotic membrane (n=9). NIS and
D3 gene expressions were shown in the fetal and maternal
sides of the placenta and amniotic membrane. Mean blood
selenium level was 66±26.5 μg/l, and median UIC was
143 μg/l. We could not demonstrate any statistically signif-
icant relationship of spot UIC and blood selenium with NIS
and D3 expression (p>0.05). Positive correlations were
found between NIS and thyroxine-binding globulin (TBG)
(r=0.3, p=0.042) and between D3 and preoperative glucose
levels (r=0.4, p=0.006). D3 and NIS genes are expressed in
term placenta and amniotic membrane; thus, in addition to
placenta, amniotic membrane contributes to regulation of
maternofetal iodine and thyroid hormone transmission. Fur-
ther studies are needed to clarify the relationship between
maternal glucose levels and placental D3 expression and
between TBG and placental NIS expression.
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Introduction
Placental type 3 iodothyronine deiodinase (D3) potentially
protects the fetus against high thyroid hormone levels of the
mother [1]. Na+/I− symporter (NIS) is a plasma membrane
glycoprotein, which mediates the active uptake of iodide into
cells with the purpose of channeling it to the developing fetus
for its proper thyroid hormone synthesis [2]. It is believed
that D3 and NIS contribute to regulation of the maternofetal
thyroid hormone metabolism.
NIS expression has been shown in the thyroid gland as
well as in other tissues such as the salivary gland and milk-
producing breast tissue [3–5]. NIS expression has also been
shown in placenta, but at lower levels than those in the
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thyroid [6, 7]. Thyroid-stimulating hormone (TSH) and io-
dide are two main regulators of NIS expression in the thyroid
gland [5, 8]. The mechanism of placental NIS expression is
not yet clear, but iodide and human chorionic gonadotropin
have been claimed to have a role [2, 9].
Iodothyronine deiodinases are selenoenzymes, which
contribute to the regulation of thyroid hormone activity in
various tissues [1]. There are three types of iodothyronine
deiodinases, type 1 iodothyronine deiodinase (D1), type 2
iodothyronine deiodinase (D2), and D3. The latter (D3) is
responsible for inner ring or 5 deiodination of T4 and T3 and
produces reverse triiodothyronine (rT3) and 3,3-T2, which
are inactive hormone products.
The uterus, placenta, and other maternofetal interfaces
such as the fetal skin, respiratory and digestive system epi-
thelium, and umbilical arteries and vein express D3 in order
to protect the fetus from high thyroid hormone levels and to
ensure that the thyroid hormones of the fetus are significantly
lower than those of the mother or other adults [1, 10–13].
The mechanism of the placental D3 expression is not well
understood. It has been claimed that estradiol and progester-
one may regulate D3 expression in the uterus [14, 15].
Selenium is a required micronutrient for normal develop-
ment, metabolism, and growth. All three iodothyronine
deiodinases (D1, D2, and D3) contain selenocysteine protein
in their active sides. According to a few animal studies, placental
D3 activity may not be affected by selenium deficiency [16, 17].
To the best of our knowledge, no human studies yet exist
about the effects of the iodide, selenium and thyroid hor-
mone levels of pregnant women on placenta NIS mRNA
expression. Our aim is to assess the distribution of NIS and
D3 expression in the fetal side of the placenta (FP), maternal
side of the placenta (MP), and the amniotic membrane and to
investigate the association between NIS and D3 expression
levels in MP and iodine, selenium, and thyroid hormone
status in human term pregnancy.
Materials and Methods
Study Protocol
A total of 49 healthy term pregnant women, who were
scheduled for a morning elective cesarean section, were
assigned to the study. Participants were aged between 22
and 43 years and at 37.5–41 weeks of gestation. Exclusion
criteria included multiple pregnancies, diagnosis of pre-
eclampsia or eclampsia, chronic diseases (DM, uremia,
etc.), previous thyroid operation, and use of thyroid hormone
preparation or antithyroid drugs. Onset of labor was another
criterion for exclusion. The study protocol was approved by
the local ethics board prior to the study, and written informed
consent of all cases was obtained.
Gestational age was determined according to the last
menstrual period and ultrasonographic biometric measure-
ments. Preoperative morning urine and blood samples were
drawn. Fasting blood glucose (FBG), insulin, antithyroid
peroxidase (anti-TPO), and antithyroglobulin (anti-TG)
levels were measured. For other analyses, blood samples
were centrifuged and kept at −80°C in a freezer.
During the operation, immediately after removal of the
placenta, samples of 2×1×1 cm were obtained from the
maternal and fetal sides of the periumbilical zone of the
placenta (by dissecting the fetal membrane), and samples
of 2 cc were obtained from the amniotic membrane and
stored in liquid nitrogen. Samples from the placenta and
amniotic membrane were kept at −80°C in a freezer.
Methods of Analysis
Urinary iodine concentration (UIC)was analyzed from spot urine
samples obtained during morning fast and frozen at −80°C. The
analysis was performed via the Sandell–Kolhoff reaction (color-
imetric method, with serik ion arsenic acid wet ash method) by
using Fisher reagent and Spectronic Genesys 20 autoanalyzer.
Total triiodothyronine (TT3), total thyroxine (TT4), free tri-
iodothyronine (FT3), free thyroxine (FT4), TSH, thyroxine-
binding globulin (TBG), transthyretin, and TG levels were
studied from serum samples and reverse triiodothyronine (rT3)
levels from plasma samples. FT3, FT4, TT3, TT4, TSH, and TG
levelswere studied in the RocheModular Analytics E170 device
with Cobas Elecsys kits manufactured by Roche Diagnostics
(RocheDiagnostics GmbH,D-68298Mannheim). Transthyretin
(prealbumin) levels were measured in the Cobas Integra 400
device with Cobas kits manufactured by Roche Diagnostics
(Roche Diagnostics GmbH, D-68298 Mannheim). rT3 levels
were measured with the RIA method by using the IDS
(Belgium) kit. TBG levels were measured with the RIA method
by using the B.R.A.H.M.S. (Berlin, Germany) kit. Serum anti-
TPO and anti-TG levels were studied by using the solid-phase,
enzyme-labeled chemiluminescent sequential immunometric as-
say and the Immulite 2000 immunoanalyzer, with Immulite
2000 anti-TPO Ab and anti-TG Siemens kits. Glucose levels
were measured with standard enzymatic method (Roche Diag-
nostics GmBH, Mannheim, Germany). Serum insulin levels
were measured by immunoradiometric assay (sandwich-type
assay) using an insulin IRMA kit (Immunotech, Prague, Czech
Republic). Seleniumwas analyzed from serum samples by using
an atomic absorption spectrometer (AAS). As samples were
prepared for analysis, isoformation was performed to thaw the
samples and to transform all selenium content into Se4+. The
analyses were performed by using the PerkinElmer AAnalyst
800Model HG-AAS instrument and the standard water addition
technique.
The thyroid ultrasonography of the 38 term pregnant
cases were done by a radiology specialist using Aloka
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5500 (Tokyo, Japan) and 7.5-MHz linear probe. Length,
width, and depth were separately measured for each
thyroid lobe, and presence of nodules or heterogeneity
characteristics were recorded. Thyroid gland volume (TV)
was calculated [18].
RT-PCR Analysis of NIS, D3, and TBP Gene Transcripts
Expression of NIS, D3, and TBP were analyzed by RT-PCR
methods followed by agarose gel electrophoresis and densito-
metric analysis of relevant bands. Human placental samples
were frozen and ground to powder under a continuous supply
of liquid nitrogen without allowing the tissue to soften. Sub-
sequently, 30 mg of placental tissue powder is taken in a 1.5-
ml Eppendorf tube, and total RNA was extracted using
RNeasy Protect kit (Qiagen, Hilden, Germany) following the
protocol described by the producer. Briefly, tissue was
pipetted in 3 ml lysis buffer and taken in a 10-ml glass tube
for homogenization by a Becker homogenizer (Palo Alto, CA)
at a speed of 1.5 for 40 strokes. Then, following the kit’s
protocol, 3 μg total RNA is used for cDNA synthesis by using
reverse transcriptase enzyme provided in Fermentas (St.
Leon-Rot, Germany) First Strand cDNA synthesis kit. The
detection and quantification of transcripts corresponding to
NIS and D3 genes were done by PCR analysis using the
following primer pairs and reaction steps: NIS forward 5′
CTCATCCTGAACCAAGTGAC 3′/NIS reverse 5′ TACATG
GAGAGCCACACCA 3′; denaturation for 5 min at 95 °C and
then 95 °C for 30 s/60 °C for 30 s/72 °C for 30 s, altogether 40
cycles, with the last extension at 72 °C for 5 min; D3 forward
5′ CCTGCTGCTTCACTCCTTG 3′/D3 reverse 5′ GCGTAG
TCGAGGATGTGCT 3′; denaturation at 95 °C for 5 min and
then 95 °C for 30 s, 60.3 °C for 30 s, and 72 °C for 30 s,
altogether 35 cycles, with the last extension at 72 °C for 5 min.
Amounts of these two transcripts were normalized by using
the levels of the general transcription factor-associated TBP,
and semiquantification was completed. PCR conditions for
TBP were as follows: TBP forward 5′ TGCACAGGAGCC
AAGAGTGAA 3′/TBP reverse 5′ CACATCACAGCTCCC
CACCA 3′; denaturation for 5 min at 95 °C and then 95 °C for
30 s/60 °C for 30 s/72 °C for 30 s, altogether 30 cycles, with
the last extension at 72 °C for 5 min. Typically, 50 pg of
cDNAwas used in all PCRs. After agarose gel electrophore-
sis, density of each band is quantified using the BioRad Gel-
Doc XR-Plus software platform (BioRad, Turkey).
Statistical Method
Statistical analyses were performed by using the SPSS 16
statistical package. Data were given as mean ± standard
deviation or median (25th, 75th percentile) according to their
distribution characteristics. Descriptive statistics and corre-
lation analyses (Pearson and Spearman) were used, as well as
t test and Mann Whitney U test to show differences between
groups. D3 and NIS expression were below the detection
limits of our technique in a number of the tissue samples,
even though the genetic material was obtained. These cases
were excluded from statistical analyses. In samples obtained
from MP, FP, and amniotic membrane of the same pregnant
women, the difference between the NIS and D3 measure-
ments was determined with the nonparametric Friedman test.
Post hoc analyses were performed. In the statistical analyses,
a p value of <0.05 was considered statistically meaningful.
Results
NIS, D3, and TBP gene expression levels were determined
with the RT-PCR method in FP, MP, and amniotic membrane
tissue samples of nine term pregnant cases in the first part of
the study (Fig. 1). The medians for D3 in the MP, FP, and
amniotic membrane (min–max) were 1.1 (0.59–1.19), 1.08
(0.95–1.28), and 0.58 (0.40–0.96), respectively. The Fried-
man test revealed a meaningful difference (p=0.03). When
the post hoc analysis was performed, similar D3 levels were
found in MP and FP (p>0.05), but D3 levels in the amniotic
membrane were lower than those in both sides of the placen-
ta (p<0.05) (Fig. 2). The median values of NIS expression
(min–max) for the MP, FP, and amniotic membrane were
0.40 (0.25–0.45), 0.39 (0.24–0.69), and 0.27 (0.18–0.46),
respectively. No statistically significant difference was ob-
served between the groups (p=0.17). NIS expression was
detected in the FP (n=6), MP (n=7), and amniotic membrane
samples (n=6). D3 expression was detected in all theMP and
FP samples, and it was found in the amniotic membrane
samples of seven cases.
In the second part of the study, D3 andNIS expression levels
were studied in the MP in the 49 term pregnant women (NIS
gene expression was below our detection limit in two cases),
and their relationship to maternal thyroid hormone, UIC, and
serum selenium level was investigated. The mean age of the
term pregnant women in the study was 31.08±5.3 years, and
their mean gestational age was 39 (38.71–39.14)weeks. The
thyroid hormone, serum selenium, UIC measurements, and
thyroid volumes of the cases are represented in Table 1.
Median UIC was 143 μg/l (minimum 8 μg/l, maximum
450 μg/l). NIS gene expression was 0.37±0.14. When the
cutoff value for UIC was taken as 150 μg/l, the NIS gene
expression levels of the cases that had UIC were below
(0.39±0.15, n=25) or above (0.36±0.13, n=22). NIS levels
of the groups were not different (p=0.4). Similarly, there
were no differences in D3 levels between the groups with
UIC levels lower or higher than 150 μg/l (0.96 (0.79–1.25),
0.91 (0.70–1.1), respectively, p=0.4).
In 49 cases, the median TSH level was found to be 2.06
(minimum 0.72, maximum 7.93)μIU/ml. Median D3 gene
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expression was 0.96 (0.76–1.14). When divided into two
groups based on the TSH levels of the women (<3
and ≥3 μIU/ml), placental D3 expression was slightly de-
creased in the TSH ≥3 μIU/ml group (0.81(0.64–1.09), n=12)
compared with the TSH <3 μIU/ml group (0.96 (0.78–1.17),
n=37), but the difference was not statistically significant
(p=0.18) [19]. There was only one woman with overt hypo-
thyroidism (D3=0.82). Expression of the NIS gene was not
significantly different between the groups with TSH levels
lower or higher than 3 μIU/ml (p=0.8).
Four term pregnant women had high anti-TPO levels
(≥34 IU/ml). The anti-TG levels of 37 cases were at the
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Fig. 1 aMaternal side of the placenta (n=4), b fetal side of the placenta
(n=4), c amniotic membrane (n=3). The number of the images shows
the analysis results of samples obtained from different women. The
numbers on the images (1–4 or 1–3) show the analysis results of
samples obtained from different patients. NIS Na+/I− symporter, D3
type 3 iodothyronine deiodinase, TBP TATAbinding protein
D3 Gene ExpressionP = 0.03
Fig. 2 The graphics represent D3 gene expression levels in the mater-
nal and fetal side of the placenta and the amniotic membrane by using
the RT-PCR method (n=7)





Duration of pregnancy (weeks) 39 (38.71–39.14)
BMI (kg/m2) 28.96±3.77
Serum selenium (μg/l) 66±26.5





TSH (μIU/ml) 2.06 (1.53–3.00)
TBG (μg/ml) 51.97±10.19
TG (ng/ml) 16.55 (11.50–35.17)
rT3 (ng/ml) 0.36 (0.30–0.47)
Transthyretin (mg/dl) 28.55 (23.47–36.47)
Glucose (mg/dl) 68 (59.75–78.21)
Insulin (μIU/ml) 10.9 (6.67–20.26)
Anti-TG (IU/ml) 10 (10–10)
Anti-TPO (IU/ml) 5.91 (5.00–13.41)
TV (ml) (n=38) 11.46 (9.05–16.44)
Data were expressed as mean ± standard deviation or median (25th,
75th percentile)
BMI body mass index, UIC urinary iodine concentration, FT3 free triiodo-
thyronine, FT4 free thyroxine, TT3 total triiodothyronine, TT4 total thyrox-
ine, TSH thyroid-stimulating hormone, TBG thyroxine-binding globulin, TG
thyroglobulin, rT3 reverse triiodothyronine,Anti-TG antithyroglobulin, Anti-
TPO antithyroid peroxidase, TV thyroid volume
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minimum measurable level. There were no cases with high
anti-TG levels.
A positive statistically significant correlation was deter-
mined between the serum TBG levels of term pregnant
women and the placental NIS expression (r=0.3, p=0.042).
Correlation of NIS expression with other parameters does
not reach a statistically significant level (Table 2).
Placental D3 gene expression was positively correlated
only with preoperative fasting blood glucose level (min 50–
max 111 mg/dl) (r=0.4, p=0.006). As represented in Table 2,
we could not demonstrate any statistically significant correla-
tions between D3 gene expression level and other parameters.
Discussion
In our study, NIS and D3 expression were studied by the RT-
PCR methods in the tissue samples obtained from the human
maternal side of placenta, which is in contact with decidua,
and the fetal side that is close to the fetal tissues and the
amniotic membrane. NIS and D3 gene expressions were
found in both sides of the placenta and amniotic membrane,
as well. To the best of our knowledge, our study is the first to
report the presence of NIS expression in the amniotic mem-
brane in the literature. The amniotic fluid is known to contain
iodide [20]. A previous study found similar iodine concen-
trations in the amniotic fluid in those who did and did not
receive iodine supplement. The authors thus claimed that
there must be a mechanism that regulates iodine in the
amniotic fluid [21]. Our study concluded that the NIS in
the amniotic membrane may contribute to iodine transmis-
sion from the mother to the fetus. Although the distribution
of NIS in the MP and the FP is not yet known in the
literature, a previous study conducted on rats found NIS
expression in the fetal side of placenta, but, different from
our study, not in the maternal side [9]. This discrepancy
between the two studies might be related to different meth-
odologies used in these works, as immunostaining methods
were used by Schroder-van der Elst et al. [9]. As mentioned
above, NIS expression was not detected in the different
surfaces of the placenta or the amniotic membrane in some
cases even though genetic material was obtained. This may
have been due to the method used, the characteristics of
tissues, or an unidentified mechanism.
Similar to a number of previous studies, we detected D3
expression in human amniotic membrane tissue samples [11,
13, 22]. These results suggest that in addition to the placenta
and the uterus, the amniotic membrane, which expresses D3,
may also regulate the transfer of thyroid hormones from the
mother to the fetus in term pregnancy [13]. In another study
with rats, D3 was similar in the fetal and maternal sides of the
placenta on day 18 of pregnancy, while day 21 had increased
D3 activity in the maternal side [23]. However, D3 expression
levels in our study were similar in both sides of the placenta,
but amniotic membrane expressed lower D3 levels than the
placenta consistent with a previous rat study [11]. These
findings suggest that placental tissues may contribute to the
regulation ofmaternofetal thyroid hormone transmissionmore
than the amniotic membrane.
One of the most significant findings of our study was the
positive correlation betweenNIS expression andmaternal serum
TBG. TBG mediates the transfer of thyroid hormones, particu-
larly thyroxine. The increasing levels of estrogen leads to in-
creased TBG during pregnancy [24, 25]. In previous years, it
was hypothesized that increased TBG in pregnancy may be “an
evolutionary adaptation” to ensure sufficient T4 and/or iodine
are provided to the fetus [26, 27]. To the best of our knowledge,
a relationship between NIS and TBG has not yet been reported
in the literature. The possible role of TBG to enhance placental
NIS expression and maternofetal iodide transmission as well as
its mechanism needs to be investigated in future studies.
Table 2 Correlation between NIS and D3 gene expression levels with
demographic characteristics and laboratory measurements
NIS D3
n=47 n=49
r p r p
Age −0.04 0.785 0.17 0.230
Duration of pregnancy 0.18 0.219 0.08 0.589
BMI 0.11 0.400 0.10 0.486
FT3 −0.15 0.298 −0.026 0.862
FT4 −0.06 0.678 −0.16 0.262
TT3 0.02 0.900 0.19 0.197
TT4 0.06 0.657 0.01 0.947
TSH −0.06 0.673 −0.19 0.180
TBG 0.3 0.042 0.11 0.434
TG −0.1 0.484 0.03 0.836
rT3 −0.08 0.600 −0.20 0.174
Transthyretin 0.16 0.261 0.24 0.100
Glucose 0.14 0.340 0.4 0.006
Insulin −0.07 0.621 −0.04 0.757
Serum selenium 0.01 0.952 −0.07 0.636
UIC −0.02 0.894 −0.027 0.858
TV −0.3 0.070 0.07 0.650
A p value of <0.05 was considered as statistically meaningful. The
Pearson correlation coefficient was used for the analyses of parameters
with normal distribution and the Spearman correlation coefficient for
others
NIS Na+ /I− symporter/TATA-binding protein, D3 type 3 iodothyronine
deiodinase/TATA-binding protein, BMI body mass index, FT3 free
triiodothyronine, FT4 free thyroxine, TT3 total triiodothyronine, TT4
total thyroxine, TSH thyroid-stimulating hormone, TBG thyroxine-
binding globulin, TG thyroglobulin, rT3 reverse triiodothyronine, UIC
urinary iodine concentration, TV thyroid volume
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Interestingly, we found a positive correlation between D3
gene expression levels and preoperative maternal FBG.
However, we did not find any correlation between maternal
serum insulin and D3 expression. Our subjects were operated
on shortly after obtaining their fasting blood glucose, and the
blood glucose levels at the time of placental removal were
not measured. D3 expression rate or half-life of the placental
D3 is not known yet. A previous in vitro study suggested that
placental D3 activity is not affected by hunger [28]. The role
of iodothyronine deiodinases and thyroid hormones in the
carbohydrate metabolism is subject of a recent debate [29,
30]. Recently, Medina et al. [30] reported that fetal and adult
pancreas in humans and mice expressed D3 obviously, while
D1 and D2 expressions were barely detected. Furthermore,
D3KO mice, whose Dio3 gene is disrupted, had impaired
insulin secretion and glucose intolerance, because of reduced
β cell mass and decreased insulin content. D3 may have a
role in regulation of carbohydrate metabolism, but it is not
clear yet. Moreover, we investigated the effects of maternal
factors such as glucose on the placental NIS and D3, but we
did not investigate their impact on the fetus. Therefore, we
could not explain the mechanism underlying this correlation
with our present knowledge.
We could not demonstrate a statistically significant rela-
tionship between spot UIC and NIS expression in term
placenta. Even though UIC may be a good indicator of
iodine intake of societies, it displays wide variations within
and between the days, particularly in pregnant women [31,
32]. In studies conducted on thyroid cell cultures, NIS was
reported to be a protein with long half-life (approximately
5 days in the presence of TSH) [8]. The half-life of placental
NIS has not been known, but it may be affected by longer-
term iodine status than the actual iodine status, which is
reflected with the UIC level. Iodine deficiency in pregnancy
results in a decrease in serum FT4 levels and an increase in
TSH and total molar T3/T4 ratio, a progressive increase in
serum TG, and an increase in the thyroid volume [24, 32].
Even though UIC in our region is significantly improved
than in previous years [33], some of the pregnant women in
our study still have low UICs. However, laboratory findings
indicate that pregnant women in our study do not have long-
term serious iodine deficiency. Moreover, in this study, pla-
cental D3 and NIS gene expressions were investigated in the
placental samples of healthy term pregnant women without
hyperthyroidism and overt hypothyroidism (except one pa-
tient) [19]. The lack of a relationship in this study between
the thyroid hormone levels and placental D3 and NIS ex-
pression levels may be attributed to the fact that the subjects
in our study did not suffer from overt thyroid function
disorder. Only semiquantitative RT-PCR methods were used
in analyses of NIS expression in this preliminary study, as we
anticipated that tissue uptake studies using radio-labeled
iodide in the tissue samples could hardly be sensitive enough
when NIS expression is not robust. Therefore, further studies
are needed.
One additional result of our study has been the informa-
tion about the serum selenium levels of pregnant women in
the region, which corroborates other studies conducted in
Turkish pregnant women [34, 35]. Despite the lack of a
recommended borderline value, the whole group of patients
seems to have low selenium levels [36]. Even though there is
an increased requirement for selenium during pregnancy,
decreased selenium levels during this physiological stage
have previously been reported [37]. Similar to previous
animal studies, our study also showed that the placental D3
expression level was not affected by the maternal serum
selenium level [16, 17, 38].
In conclusion, we showed D3 and NIS expressions in the
maternal and fetal sides of the placenta and the amniotic
membrane in human term pregnancy by the total mRNA
RT-PCR method. In addition to the placental NIS and D3
expressions, the amniotic membrane also contributes to the
regulation of maternofetal iodine and thyroid hormone trans-
mission by expressing NIS and D3. The placenta and amni-
otic membrane express NIS to contribute to providing iodine
from mother to fetus and D3 in order to protect the fetus
against thyroid hormones in term pregnant women. Howev-
er, while D3 expression was probably similar throughout the
placenta, it was lower in the amniotic membrane, and thus,
the effectiveness of placenta in the regulation of maternofetal
thyroid hormone transmission could be higher than that of
the amniotic membrane. In healthy term pregnant women
without overt thyroid function disorder, we could not find
any significant differences of placental D3 and NIS gene
expressions with regard to spot UIC and thyroid hormone
levels. Our preliminary study demonstrated a positive corre-
lation between NIS gene expression and TBG in term preg-
nant women. The possible role of TBG in placental NIS
expression and the regulation of maternofetal iodide trans-
mission needs to be studied. Likewise, the positive correla-
tion between preoperative glucose levels and D3 should be
investigated.
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